Immune Checkpoint Inhibitors May Be Overused at End of Life
With responses to ICIs taking 2 to 3 months, administration of these therapies to patients with poor life expectancies may not be appropriate.
With responses to ICIs taking 2 to 3 months, administration of these therapies to patients with poor life expectancies may not be appropriate.
Genetic testing provided important information beyond personal and family history.
Identifying the optimal interval from TURP to prostatectomy is important.
αCAR19 could be useful in patients in long-term remission after CAR-T treatment.
Only about one-third of patients required hospital admission.
These characteristics may account for enhanced antitumor efficacy in multiple myeloma.
The odds of postoperative complications were lower at top-ranked hospitals compared with non–top-ranked hospitals across a specific subset of cancer types.
Patterns of genetic alterations could guide management.
The combination warrants no further study in these patients.
The risk may be transient, as immune function recovered in late phases of treatment.